

## SGN-B7H4V

An investigational antibody-drug conjugate directed to B7-H4

### Anti-B7-H4 antibody


Fully human IgG1 monoclonal antibody that binds to B7-H4

### Protease-cleavable mc-vc linker

Covalently attaches MMAE to the antibody and releases agent within the target cell

### MMAE

Microtubule-disrupting agent



### Target: B7-H4

- Member of the B7 family of immune checkpoint ligands and has been shown to negatively regulate T-cell function<sup>1,2</sup>
- Inhibits T-cell proliferation and cytokine production<sup>1-3</sup>
- B7-H4 expression elevated across a broad range of solid tumors, including cholangiocarcinoma and ovarian, breast, endometrial, gallbladder, and squamous non-small cell lung cancers<sup>4-11</sup>

### Proposed Mechanism of Action<sup>12-15,a</sup>

- Direct cytotoxicity<sup>12</sup>
- Bystander effect<sup>13</sup>
- Antibody-dependent cellular cytotoxicity<sup>12</sup>
- Antibody-dependent cellular phagocytosis<sup>12</sup>
- Immunogenic cell death<sup>14,15</sup>


**IgG1:** immunoglobulin G1; **mc-vc:** maleimidocaproyl-valine-citrulline; **MMAE:** monomethyl auristatin E

<sup>a</sup>Based on preclinical data

1. Sica GL. *Immunity*. 2003; 849-61. 2. Zang X. *Proc Natl Acad Sci USA*. 2003; 10388-92. 3. Dangaj D. *Cancer Res*. 2013; 4820-9. 4. Leong SR. *Mol Pharm*. 2015; 1717-29. 5. Liang L. *Hum Pathol*. 2016; 1-6. 6. Liu CL. *Eur Rev Med Pharmacol Sci*. 2016; 4466-73. 7. Zhao X. *Oncol Rep*. 2016; 419-27. 8. Bregar A. *Gynecol Oncol*. 2017; 446-52. 9. Schalper KA. *Clin Cancer Res*. 2017; 370-8. 10. Xie N. *Cell Death Dis*. 2017; 3205. 11. Altan M. *NPJ Breast Cancer*. 2018; 40. 12. Gray E. *SITC 2021: EP854*. 13. Burton JK. *AAPS J*. 2019; 12. 14. Gray E. *AACR 2022: Poster 1261*. 15. Ulrich M. *SITC 2022: Poster 1190*.


**The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.**





### Proposed Mechanism of Action<sup>1,a</sup>

- 1 Binds to B7-H4
- 2 Complex internalization and trafficking
- 3 MMAE release
- 4 Microtubule disruption
- 5 Cell cycle arrest and apoptotic cell death



MMAE: monomethyl auristatin E; NK: natural killer

<sup>a</sup>Based on preclinical data

1. Data on file.

### Clinical Trials



RECRUITING

SGNB7H4V-001: Advanced solid tumors (NCT05194072) SGN-B7H4V

Phase 1

Phase 2

Phase 3

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.